Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 6/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810508 | 0.87 | NR1I2 (0.48) | BRD4KDM4ECCR2NR1I2 | |
| SCHEMBL3906066 | 0.86 | ACLY (0.43) | BRD4CCR2ACLY | |
| SCHEMBL3902067 | 0.86 | ACLY (0.53) | BRD4CCR2ACLYNR1I2 | |
| SCHEMBL3906639 | 0.84 | ACLY (0.54) | BRD4ACLY | |
| SCHEMBL3906452 | 0.84 | ACLY (0.54) | BRD4CCR2ACLY | |
| SCHEMBL1812324 | 0.84 | CCR2 (0.41) | BRD4CCR2ACLYNR1I2 | |
| SCHEMBL1811874 | 0.82 | DAO (0.38) | ACLY | |
| SCHEMBL1810258 | 0.81 | ACLY (0.43) | ACLY | |
| SCHEMBL4361093 | 0.80 | DAO (0.36) | BRD4ACLY | |
| SCHEMBL3906458 | 0.79 | ACLY (0.47) | CCR2ACLYTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4682207-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | claimed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | claimed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | BRD4 2606/4885KDM4E 2229/4885CCR2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.